Exon Skipping Stocks
Biopharmaceutical innovators in this space leverage antisense oligonucleotides to modulate pre-mRNA splicing, effectively bypassing genetic mutations to restore the production of functional proteins. These developers target rare, monogenic disorders where traditional small molecules fail, creating high-barrier intellectual property around sequence-specific genetic correction.
As of Oct 23, 2026, Exon Skipping has 2 US-listed companies worth $2B combined. The median member moved +2.3% over the past week; SRPT led at +3.7% and TRDA trailed at +0.9%.